Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT03904563
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
  • chest radiation — RADIATION
    split-course chest radiation
  • concurrent chemotherapy — DRUG
    weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation

Study Details

This prospective phase II study is to determine the efficacy and safety of bevacizumab maintenance therapy after concurrent chemoradiotherapy in locally advanced lung adenocarcinoma

Key Dates

First listed
Apr 5, 2019
Start date
Jan 1, 2019
Status verified
Mar 2023
Primary completion
Dec 10, 2021
Completion
Dec 15, 2022

Study Design

Enrollment
27 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.

Primary Outcome Measure

Progression-free survival [ Time Frame: 3-year ]

Related Studies